Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.

Krakowski MI, Czobor P.

J Clin Psychiatry. 2012 Jan;73(1):74-80. doi: 10.4088/JCP.11m07238.

PMID:
22152404
2.

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.

Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB.

Arch Gen Psychiatry. 2006 Jun;63(6):622-9.

PMID:
16754835
3.

Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.

Krakowski MI, Czobor P.

Schizophr Bull. 2014 Jul;40(4):886-94. doi: 10.1093/schbul/sbt117.

4.

Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.

Krakowski MI, Czobor P, Nolan KA.

J Clin Psychopharmacol. 2008 Oct;28(5):485-93. doi: 10.1097/JCP.0b013e3181855cd6.

PMID:
18794642
5.

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.

Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Lieberman JA.

J Clin Psychopharmacol. 2004 Apr;24(2):225-8.

PMID:
15206671
6.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
7.

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group..

J Clin Psychiatry. 2011 Jul;72(7):955-61. doi: 10.4088/JCP.10m06529.

PMID:
21824456
8.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.

Am J Psychiatry. 2002 Jun;159(6):1018-28.

PMID:
12042192
10.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
11.

Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.

Krakowski M, Czobor P, Citrome L.

Schizophr Res. 2009 May;110(1-3):95-102. doi: 10.1016/j.schres.2009.02.006.

PMID:
19269139
12.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
13.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA.

Am J Psychiatry. 2004 Jun;161(6):985-95.

PMID:
15169686
14.
15.

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.

Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA.

Psychiatr Serv. 2001 Nov;52(11):1510-4.

PMID:
11684748
16.

Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.

Krakowski M, Czobor P.

Schizophr Res. 2011 Aug;130(1-3):27-33. doi: 10.1016/j.schres.2011.04.005.

PMID:
21549568
17.

Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.

Volavka J, Nolan KA, Kline L, Czobor P, Citrome L, Sheitman B, Lindenmayer JP, McEvoy J, Lieberman JA.

Schizophr Res. 2005 Jul 1;76(1):127-9. No abstract available.

PMID:
15927808
18.

Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.

Fond G, Boyer L, Favez M, Brunel L, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq, Faget C, Gabayet F, Laouamri H, Lancon C, Le Strat Y, Misdrahi D, Rey R, Passerieux C, Schandrin A, Schurhoff F, Tronche AM, Urbach M, Vidalhet P, Llorca PM, Pelissolo A; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group..

Psychopharmacology (Berl). 2016 Feb;233(4):571-8. doi: 10.1007/s00213-015-4167-8.

PMID:
26630993
19.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
20.
Items per page

Supplemental Content

Support Center